kidney issues with semaglutide in patients overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial semaglutide and chronic kidney disease

Exposure to oral semaglutide was also slightly increased when administered with omeprazole compared with when administered alone (AUC 024 h,Day10 ), but this difference was not statistically significant (estimated treatment ratio: 1.13

The gut-brain axis, that is, the bidirectional communication system between the gut and the brain, has gained central importance in PD research over the past 20 years

Additionally, the available clinical trials did not measure the biomarkers of oxidative damage, so its mechanism of action may not be indeed related to the antioxidant effects

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body